APGN - Apexigen Inc
IEX Last Trade
0.4157
0.009 2.069%
Share volume: 7,706
Last Updated: Tue 08 Aug 2023 08:10:05 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.41
0.01
2.11%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-5.33%
1 Month
-3.07%
3 Months
1.78%
6 Months
-72.68%
1 Year
-95.94%
2 Year
-95.86%
Key data
Stock price
$0.42
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.33 - $11.46
52 WEEK CHANGE
-$0.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO:
Region: US
Website:
Employees: 29
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website:
Employees: 29
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.
Recent news